Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04417361 · ClinicalTrials.gov registry record · Phase 2
Galcanezumab for Vestibular Migraine
A Phase 2 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT04417361 is a Phase 2 study that has completed, run by University of California, San Francisco. The registered enrollment target is 40 participants.
The verdict
NCT04417361, a Phase 2 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
Vestibular migraine (VM) has been recognized a distinct subtype of migraine that causes dizziness as the predominant symptom. Criteria for diagnosis have been adopted by the Barany Society. Previous epidemiological research from the investigators has shown that VM affects 2.7% of the adult population of the United States. Yet, despite its high prevalence, there is very little data upon which to guide treatment decisions. A Cochrane review in 2015 concluded that there were no placebo controlled trials in VM, and none have been done since then. The investigators recently developed and validated a patient reported outcome tool for VM called VM-PATHI (VM- Patient Assessment Tool and Handicap Inventory). Anecdotal evidence suggests that CGRP antagonists, such as Galcanezumab, may be effective in reducing or eliminating symptoms in VM. Therefore, the investigators propose a pilot study of changes in VM-PATHI scores, comparing active treatment (Galcanezumab) to placebo arms.
Interventions
- DRUG Placebo
- DRUG Galcanezumab Prefilled Syringe
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2020-09-18 |
| Est. Completion | 2023-09-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04417361
The ClinicalTrials.gov registry entry for NCT04417361 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04417361 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04417361 about?
NCT04417361 is a clinical study titled "Galcanezumab for Vestibular Migraine". Vestibular migraine (VM) has been recognized a distinct subtype of migraine that causes dizziness as the predominant symptom. Criteria for diagnosis have been adopted by the Barany Society. Previous epidemiological research from the investigators has shown that VM affects 2.7% of the adult populatio...
What is the current status of trial NCT04417361?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2020-09-18. Estimated completion is 2023-09-29.
What interventions are being tested in trial NCT04417361?
The interventions under investigation include: Placebo (DRUG), Galcanezumab Prefilled Syringe (DRUG).
Who is sponsoring clinical trial NCT04417361?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.